Spero Therapeutics, Inc. (SPRO) SEC filings

SPRONasdaqPharmaceutical PreparationsFiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 12, 2026Score 6/30

$1.00−0.02 (-1.96%)

Close on Nov 12, 2026Market cap $58.23MP/E –Yield –

SEC filings

40 of Spero Therapeutics's most recent filings on SEC EDGAR

Document	Form	Period	Filed	Source
Current report	8-K	Nov 12, 2026	Nov 12, 2026	SEC EDGAR
Quarterly report	10-Q	Sep 30, 2026	Nov 12, 2026	SEC EDGAR
Current report	8-K	Nov 9, 2026	Nov 10, 2026	SEC EDGAR
Current report	8-K	Oct 26, 2026	Oct 27, 2026	SEC EDGAR
Current report	8-K	Aug 28, 2026	Aug 28, 2026	SEC EDGAR
Current report	8-K	Aug 12, 2026	Aug 12, 2026	SEC EDGAR
Quarterly report	10-Q	Jun 30, 2026	Aug 12, 2026	SEC EDGAR
Current report	8-K	Jul 8, 2026	Jul 14, 2026	SEC EDGAR
Current report	8-K	Jun 23, 2026	Jun 25, 2026	SEC EDGAR
Current report	8-K	Jun 17, 2026	Jun 22, 2026	SEC EDGAR
Quarterly report	10-Q	Mar 31, 2026	May 13, 2026	SEC EDGAR
Current report	8-K	May 13, 2026	May 13, 2026	SEC EDGAR
Proxy statement	DEF 14A	Jun 23, 2026	Apr 27, 2026	SEC EDGAR
Current report	8-K	Mar 26, 2026	Mar 26, 2026	SEC EDGAR
Annual report	10-K	Dec 31, 2025	Mar 26, 2026	SEC EDGAR
Current report	8-K	Jan 30, 2026	Jan 30, 2026	SEC EDGAR
Current report	8-K	Dec 19, 2025	Dec 19, 2025	SEC EDGAR
Current report	8-K	Nov 13, 2025	Nov 13, 2025	SEC EDGAR
Quarterly report	10-Q	Sep 30, 2025	Nov 13, 2025	SEC EDGAR
Current report	8-K	Aug 12, 2025	Aug 12, 2025	SEC EDGAR
Quarterly report	10-Q	Jun 30, 2025	Aug 12, 2025	SEC EDGAR
Current report	8-K	Jun 12, 2025	Jun 18, 2025	SEC EDGAR
Current report	8-K	May 28, 2025	May 28, 2025	SEC EDGAR
Current report	8-K	May 13, 2025	May 13, 2025	SEC EDGAR
Quarterly report	10-Q	Mar 31, 2025	May 13, 2025	SEC EDGAR
Proxy statement	DEF 14A	Jun 12, 2025	Apr 28, 2025	SEC EDGAR
Current report	8-K	Apr 22, 2025	Apr 28, 2025	SEC EDGAR
Current report	8-K	Mar 27, 2025	Mar 27, 2025	SEC EDGAR
Annual report	10-K	Dec 31, 2024	Mar 27, 2025	SEC EDGAR
Current report	8-K	Feb 25, 2025	Feb 28, 2025	SEC EDGAR
Current report	8-K	Jan 7, 2025	Jan 10, 2025	SEC EDGAR
Current report	8-K	Nov 14, 2024	Nov 14, 2024	SEC EDGAR
Quarterly report	10-Q	Sep 30, 2024	Nov 14, 2024	SEC EDGAR
Current report	8-K	Oct 29, 2024	Oct 29, 2024	SEC EDGAR
Current report	8-K	Sep 9, 2024	Sep 10, 2024	SEC EDGAR
Current report	8-K	Aug 5, 2024	Aug 5, 2024	SEC EDGAR
Quarterly report	10-Q	Jun 30, 2024	Aug 5, 2024	SEC EDGAR
Current report	8-K	May 29, 2024	Jun 3, 2024	SEC EDGAR
Current report	8-K	May 15, 2024	May 15, 2024	SEC EDGAR
Quarterly report	10-Q	Mar 31, 2024	May 15, 2024	SEC EDGAR

Where these numbers come from

Parsed from the XBRL in Spero Therapeutics's annual and quarterly filings with the SEC
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is SPRO.

Compare: SPRO vs KROS · SPRO vs OCUL · SPRO vs FULC · SPRO vs GOSS · SPRO vs TNGX

Revenue growth2.5% · median -46.5%

Operating margin-67.3% · median -181.3%

Net margin-71.0% · median -159.5%

Company	Revenue	Growth
GOSS	$78.42M	+78.0%
OCUL	$50.38M	-9.7%
SPRO	$41.56M	+2.5%
KROS	$40.42M	-83.4%
FULC	–	–
TNGX	$0	-100.0%

Company

Exchange: Nasdaq
Industry: Pharmaceutical Preparations
Fiscal year ends: December 31
Employees: 25
Held by institutions: 36.9%
Auditor: PricewaterhouseCoopers LLP
SEC CIK: 1701108

Advertisement
300 × 250

See a number that looks wrong?